Agenda
8:30 AM — 12:00 PM
#21: The Sunshine Act: Understanding the Essentials of Compliance8:30 AM — 12:00 PM
#22: Preparing for a US FDA Advisory Committee Meeting8:30 AM — 12:00 PM
#23: Leadership: How to Organize and Lead People in Group Work9:00 AM — 5:00 PM
#40: Analysis of Safety Data from Clinical Trials9:00 AM — 5:00 PM
#41: Quality Oversight of CROs-Clinical Vendors9:00 AM — 5:00 PM
#42: Regulatory Affairs for Biologics9:00 AM — 5:00 PM
#43: Clinical Statistics for Nonstatisticians9:00 AM — 5:00 PM
#44: Quality by Design: From Theory to Practice9:00 AM — 5:00 PM
#45: Risk Management Plan1:00 PM — 4:30 PM
#33: Bayesian Evidence Synthesis and Network Meta-analysis8:30 AM — 10:00 AM
Bringing the Patient Voice to Clinical Development8:30 AM — 10:00 AM
Delivering Value Through Medical Content to Health Care Providers8:30 AM — 10:00 AM
Design and Sample Size Planning for Multiregional Clinical Trials8:30 AM — 10:00 AM
Formal Dispute Resolution at CDER: When, Why, and How8:30 AM — 10:00 AM
Global Clinical Trials Symposium: Opportunities and Challenges8:30 AM — 10:00 AM
Global Pediatric Development: We Are Making Progress8:30 AM — 10:00 AM
Implementation of Quality by Design: Progress Update8:30 AM — 10:00 AM
Making Better Go/No-Go Decisions: Improving Success Rates and Reducing Costs8:30 AM — 10:00 AM
Pioneering Regenerative Medicine: Trends in Regulations for New Therapy8:30 AM — 10:00 AM
Protocol Deviations: Finding the Yellow Brick Road (Part 1 of 2)8:30 AM — 10:00 AM
Risk Management in the US, EU, and Asia: Where Are We Now?8:30 AM — 10:00 AM
Stage Gate Decision-Making Workshop (Part 1 of 2)8:30 AM — 10:00 AM
The Twitter Value Proposition for Life Science Professionals11:00 AM — 12:30 PM
Driving Toward Standardization: Overcoming Barriers - eDM, eTMF, and CTMS11:00 AM — 12:30 PM
Electronic Clinical Outcome Assessments: Coming to a Device Near You!11:00 AM — 12:30 PM
Engaging Patients through Digital and Social Media Communities11:00 AM — 12:30 PM
Fact or Fiction: Patient Engagement in the Drug Development Process11:00 AM — 12:30 PM
New Approaches to International Collaboration Between Regulators (Part 2 of 2)11:00 AM — 12:30 PM
Pediatric Drug Development: Lessons Learned During FDASIA Implementation11:00 AM — 12:30 PM
Protocol Deviations: Finding the Yellow Brick Road (Part 2 of 2)11:00 AM — 12:30 PM
R&D and Technology Outsourcing Today: An Industry Update11:00 AM — 12:30 PM
Regulatory Submissions: Better, Faster, and Cheaper11:00 AM — 12:30 PM
Stage Gate Decision-Making Workshop (Part 2 of 2)11:00 AM — 12:30 PM
Strategic Quantitative Thinking: Designing a Roadmap for Innovation2:30 PM — 4:00 PM
Plenary Session & Keynote Address8:00 AM — 9:30 AM
Bioinformatics and Translational Medicine8:00 AM — 9:30 AM
CDRH Town Hall8:00 AM — 9:30 AM
Clinical Outcomes Assessment and Patient Engagement Symposium8:00 AM — 9:30 AM
CMC Development of Breakthrough Therapies8:00 AM — 9:30 AM
Collaboration in R&D: What’s New for TransCelerate BioPharma?8:00 AM — 9:30 AM
Communicating Clinical Trial Results: Targeting the Patient Audience8:00 AM — 9:30 AM
Covering Industry Trends in the Biomedical Industry8:00 AM — 9:30 AM
Drug Development and the Virtual Company8:00 AM — 9:30 AM
Nanotechnology: Application to Medical Products8:00 AM — 9:30 AM
Pharmaceuticals and Medical Devices Agency (PMDA) Town Hall8:00 AM — 9:30 AM
Prescription Drug Marketing Regulatory Primer8:00 AM — 9:30 AM
Regulated Product Submissions and eCTD 4: The Path to Progress8:00 AM — 9:30 AM
Regulatory and GCP Quality Trends in Emerging Markets10:30 AM — 12:00 PM
Development of an Integrated Orphan Drug Framework in Canada10:30 AM — 12:00 PM
Device and Diagnostic Innovation10:30 AM — 12:00 PM
Europe Town Hall10:30 AM — 12:00 PM
GCP Inspection Findings: A Roundtable Discussion10:30 AM — 12:00 PM
Improving the Informed Consent Process10:30 AM — 11:30 AM
Industry Trends, Successes, and Failures in Orphan and Rare Disease Therapeutics10:30 AM — 11:30 AM
Juvenile Animal Studies and Pediatric Nonclinical Development10:30 AM — 12:00 PM
Manufacturing Challenges for Breakthrough Products10:30 AM — 12:00 PM
Networking: It's Not What You Know, But Who You Know!10:30 AM — 12:00 PM
Preparing for a Successful Product Launch10:30 AM — 12:00 PM
Risk-Based Monitoring: From Concept to Practice10:30 AM — 12:00 PM
Update on Postmarketing Safety Reporting1:30 PM — 3:00 PM
Adapting GCPs to Evolving Drug Development Paradigm (Part 1 of 2)1:30 PM — 3:00 PM
Asia Town Hall1:30 PM — 3:00 PM
Breakthrough Therapy Designation: One Year After1:30 PM — 3:00 PM
EMA-FDA GCP Initiative: Current Status and Future Perspectives1:30 PM — 3:00 PM
Embracing Change: The New Face of Clinical Data Management1:30 PM — 3:00 PM
FDA Enforcement Update: Advertising and Promotion1:30 PM — 3:00 PM
Improving Investigative Site Selection Practices1:30 PM — 3:00 PM
In-Sourcing, Out-Sourcing: Where Do We Go from Here?1:30 PM — 3:00 PM
Introducing CDER's Office of Pharmaceutical Quality1:30 PM — 3:00 PM
Organs on a Chip: The Future of Efficacy and Safety Testing1:30 PM — 3:00 PM
Virtual Teams in Clinical Development1:30 PM — 3:00 PM
Yes and ... Applying Improvisational Skills to Improve Innovation3:30 PM — 5:00 PM
Adapting GCPs to Evolving Drug Development Paradigm (Part 2 of 2)3:30 PM — 5:00 PM
Building a Site Budget from the Ground Floor3:30 PM — 5:00 PM
Development of Central Nervous System Drugs with Abuse Potential3:30 PM — 5:00 PM
Electronic Standardized Study Data: Regulatory Considerations3:30 PM — 5:00 PM
FDA - Health Canada Regulatory Cooperation Council (RCC) Town Hall3:30 PM — 5:00 PM
Gene Therapy Symposium3:30 PM — 5:00 PM
International Regulatory Advertising and Promotion Considerations3:30 PM — 5:00 PM
Key Subgroup Analysis Issues in Clinical Trials3:30 PM — 5:00 PM
Orphan Drugs and Treatment of Rare Diseases in Asia3:30 PM — 5:00 PM
Perfecting the Protocol: Designing Studies for Success3:30 PM — 5:00 PM
Power Up! Give Your Brain a Vacation3:30 PM — 5:00 PM
Prequalification of Medicines for Neglected Tropical Diseases3:30 PM — 5:00 PM
The Regulatory Writing Game Show3:30 PM — 5:00 PM
Transforming Culture and Mindsets to Deliver a Higher Quality eTMF3:30 PM — 4:30 PM
Utilizing 505(b)(2) to Accelerate Drug Development Plans8:00 AM — 9:30 AM
Balancing Manufacturing Quality Improvements and Drug Shortage8:00 AM — 9:30 AM
Designing Smarter and More Cost-Effective Phase 1 Protocols8:00 AM — 9:30 AM
ICH Update: Emerging Guidelines8:00 AM — 9:30 AM
International Cooperation in Rare Disease Research8:00 AM — 9:30 AM
Regulatory Strategic Plan: Don’t Start Development Without One8:00 AM — 9:30 AM
Seeing Is Believing! Good Graphic Design Principles for Medical Research8:00 AM — 9:30 AM
Signal Detection: Challenges and Strategic Aspects8:00 AM — 9:30 AM
Transforming ICH Toward Greater Global Harmonization8:00 AM — 9:00 AM
Why Does Drug Development Need Project Management?10:30 AM — 12:00 PM
Career Planning and Limitations for Mid- to Upper-Level Project Managers10:30 AM — 12:00 PM
Clinical Supply Symposium10:30 AM — 12:00 PM
Expanding the Scope: Empowering the Public in Pharmacovigilance10:30 AM — 11:30 AM
Field-Based Medical Communications on a Global Scale10:30 AM — 12:00 PM
From the Protocol to the Patient: Clinical Trial Data Disclosure10:30 AM — 12:00 PM
GCP Audits in a Risk-Based Environment10:30 AM — 12:00 PM
Implementation of GDUFA: Progress and Expectations10:30 AM — 12:00 PM
Maximizing the Potential of Your EDC System10:30 AM — 12:00 PM
Project Management Basics: Creating a High-Level Project Plan10:30 AM — 12:00 PM
Public-Private Partnerships: An Innovative Strategy for Patient Registries10:30 AM — 12:00 PM
Risk-Based Monitoring Symposium10:30 AM — 12:00 PM
Site Certification of Early Phase Research Units: An International Perspective10:30 AM — 12:00 PM
Site Selection and Feasibility Symposium10:30 AM — 12:00 PM
Update from the FDA-EMA Parallel Assessment Pilot10:30 AM — 11:30 AM
Vendor Selection for a Small Company1:30 PM — 3:00 PM
Abstract and Article Publication Opportunities with DIA1:30 PM — 3:00 PM
Challenges and Opportunities Facing FDA’s International Posts1:30 PM — 3:00 PM
Complex Drug Projects: Complex Project Management1:30 PM — 3:00 PM
Costing Strategies for Sustainable Drug Development1:30 PM — 3:00 PM
EU Clinical Trial Data Transparency Debate: Where Are We?3:30 PM — 5:00 PM
Benefit-Risk Evaluation in Drug Development3:30 PM — 5:00 PM
CMC Regulatory Pathways in the Emerging Markets: Focus on Asia Pacific3:30 PM — 5:00 PM
End-to-End Data and Metadata in Today's Clinical Trials3:30 PM — 5:00 PM
Health Authority Meeting Preparation: There Are No Do-Overs3:30 PM — 5:00 PM
Patient Voice in Decision Making: How Are Regulators Making This Work?3:30 PM — 5:00 PM
Product Crisis Management: Crisis, What Crisis?3:30 PM — 5:00 PM
Regulatory Challenges for Orphan Medicines3:30 PM — 5:00 PM
Sustainable Solutions for Global Clinical Research Site Documentation3:30 PM — 5:00 PM
The Realities of Late Life Cycle Management for Very Old Legacy Brands3:30 PM — 5:00 PM
The Sponsor-Vendor-Vendor Relationship: A Fine Balance3:30 PM — 5:00 PM
Women as Transformational Leaders9:00 AM — 10:30 AM
CDER Town Hall (Part 1 of 2)9:00 AM — 10:30 AM
Exploring Responder-Patient Clinical Study Design Approaches9:00 AM — 10:30 AM
GCP Quality Agreements9:00 AM — 10:30 AM
Hot Topics in Medical Devices Labeling: US and Global9:00 AM — 10:30 AM
Keeping It Together: Syncing CRO Data and Metrics9:00 AM — 10:00 AM
Qualifying a Software Vendor in a Regulated Industry9:00 AM — 10:30 AM
Safety in Special Situations: Stem Cells, Vaccines, and Combination Products9:00 AM — 10:30 AM
Today's Dynamic Medical Science Liaison Environment10:45 AM — 12:15 PM
A Hitchhiker's Guide to Working with Management Consultants10:45 AM — 12:15 PM
Bringing Quality to Quality Metrics10:45 AM — 12:15 PM
CDER Town Hall (Part 2 of 2)10:45 AM — 12:15 PM
Innovative Patient Recruitment Solutions for Rare Disease Clinical Trials10:45 AM — 12:15 PM
Risk-Based Monitoring: Where We Are and Where We Are Headed10:45 AM — 12:15 PM
Trends in Biosimilars Regulation Within Developed and Emerging MarketsHave an account?